Skip Nav Destination
Issues
1 July 2014
-
Cover Image
Cover Image
![issue cover]()
Loss of S6 phosphorylation as a biomarker of response to PI3K/mTOR pathway inhibition. The representative image shows immunohistochemical staining for phosphorylated S6 protein (ser235-236) in SUM190 breast cancer cell line xenografts treated with the pan-PI3K inhibitor BKM120. For details, see the article by O'Brien and colleagues on page 3507 of this issue.Close Modal - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Issue Sections
Highlights
CCR Translations
CCR Perspectives in Drug Approval
Statistics in Clinical Cancer Research
Molecular Pathways
Review
Human Cancer Biology
MET Is a Potential Target across All Papillary Renal Cell Carcinomas: Result from a Large Molecular Study of pRCC with CGH Array and Matching Gene Expression Array
Laurence Albiges; Justine Guegan; Audrey Le Formal; Virginie Verkarre; Nathalie Rioux-Leclercq; Mathilde Sibony; Jean-Christophe Bernhard; Philippe Camparo; Zahira Merabet; Vincent Molinie; Yves Allory; Cedric Orear; Sophie Couvé; Sophie Gad; Jean-Jacques Patard; Bernard Escudier
Cancer Therapy: Preclinical
Disruption of Follicular Dendritic Cells–Follicular Lymphoma Cross-talk by the Pan-PI3K Inhibitor BKM120 (Buparlisib)
Alba Matas-Céspedes; Vanina Rodriguez; Susana G. Kalko; Anna Vidal-Crespo; Laia Rosich; Teresa Casserras; Patricia Balsas; Neus Villamor; Eva Giné; Elías Campo; Gaël Roué; Armando López-Guillermo; Dolors Colomer; Patricia Pérez-Galán
Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT
Neil A. O'Brien; Karen McDonald; Luo Tong; Erika von Euw; Ondrej Kalous; Dylan Conklin; Sara A. Hurvitz; Emmanuelle di Tomaso; Christian Schnell; Ronald Linnartz; Richard S. Finn; Samit Hirawat; Dennis J. Slamon
Imaging, Diagnosis, Prognosis
Improved Differentiation of Benign and Malignant Breast Tumors with Multiparametric 18Fluorodeoxyglucose Positron Emission Tomography Magnetic Resonance Imaging: A Feasibility Study
Katja Pinker; Wolfgang Bogner; Pascal Baltzer; Georgios Karanikas; Heinrich Magometschnigg; Peter Brader; Stephan Gruber; Hubert Bickel; Peter Dubsky; Zsuzsanna Bago-Horvath; Rupert Bartsch; Michael Weber; Siegfried Trattnig; Thomas H. Helbich
Treatment Response Evaluation Using 18F-FDOPA PET in Patients with Recurrent Malignant Glioma on Bevacizumab Therapy
Johannes Schwarzenberg; Johannes Czernin; Timothy F. Cloughesy; Benjamin M. Ellingson; Whitney B. Pope; Tristan Grogan; David Elashoff; Cheri Geist; Daniel H.S. Silverman; Michael E. Phelps; Wei Chen
Author Choice
TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance
Laxmi Silwal-Pandit; Hans Kristian Moen Vollan; Suet-Feung Chin; Oscar M. Rueda; Steven McKinney; Tomo Osako; David A. Quigley; Vessela N. Kristensen; Samuel Aparicio; Anne-Lise Børresen-Dale; Carlos Caldas; Anita Langerød
Cancer Therapy: Clinical
Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q-Patients with MDS and AML
Katharina Blatt; Harald Herrmann; Gregor Hoermann; Michael Willmann; Sabine Cerny-Reiterer; Irina Sadovnik; Susanne Herndlhofer; Berthold Streubel; Werner Rabitsch; Wolfgang R. Sperr; Matthias Mayerhofer; Thomas Rülicke; Peter Valent
Predictive Biomarkers and Personalized Medicine
Prognostic and Therapeutic Implications of Aromatase Expression in Lung Adenocarcinomas with EGFR Mutations
Mikihiro Kohno; Tatsuro Okamoto; Kenichi Suda; Mototsugu Shimokawa; Hirokazu Kitahara; Shinichiro Shimamatsu; Hideyuki Konishi; Tsukihisa Yoshida; Mitsuhiro Takenoyama; Tokujiro Yano; Yoshihiko Maehara
Letters to the Editor
Advertisement
